JBT 3002

Drug Profile

JBT 3002

Alternative Names: L 3002

Latest Information Update: 24 Aug 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jenner Biotherapies (CEASED)
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants; Nitric oxide synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chemotherapy-induced damage

Most Recent Events

  • 24 Aug 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 24 Aug 2005 Discontinued - Preclinical for Chemotherapy induced damage (Prevention) in USA (unspecified route)
  • 16 Feb 2000 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top